Carmine Therapeutics Leadership

Don Haut, Ph.D.

CEO

Don brings more than two decades of healthcare experience. He was previously the Chief Business Officer of AskBio, where he led the firm’s business development activities and spearheaded its $4 billion acquisition by Bayer AG.

Tenzin Gocha, Ph.D.

Director, Scientific & Business Operations

Tenzin is an Associate at EVX Ventures and a founding member of Carmine Therapeutics. He obtained his Ph.D. in Molecular Pharmacology from New York University Medical Center.

John Robblee, Ph.D.

Vice President, CMC

Dr. Robblee brings over 15 years of development experience to the Chemistry, Manufacturing and Controls (CMC) function at Carmine. He received his Ph.D. from the University of California, Berkeley in biophysical chemistry.

Ozan Alkan, Ph.D.

Associate Vice President, Molecular Biology

Dr. Alkan's passion for gene therapy started 20 years ago while working in Germany's first gene therapy group and trial when he was a visiting student in Philip Leboulch's lab.

Ronne Yeo, Ph.D.

Vice President, Discovery

As founding member of Carmine Therapeutics, Ronne built and led the research team to create the REGENT™ Platform. Ronne obtained his Ph.D. in Biological Sciences from the National University of Singapore.

Board of Directors

XQ Lin

Co-Founder & Chairman

XQ is the Founder and Managing Partner of EVX Ventures. He is a synergistic business partner to entrepreneurial scientists/innovators, with a track record in taking technologies from concept to commercial reality.

Prof. Harvey Lodish

Scientific Co-Founder & Board Member

Professor Lodish is a Founding Member of the Whitehead Institute for Biomedical Research. He is a Professor of Biology and a Professor of Biological Engineering at the Massachusetts Institute of Technology (MIT).

Don Haut, Ph.D.

CEO

Don brings more than two decades of healthcare experience. He was previously the Chief Business Officer of AskBio, where he led the firm’s business development activities and spearheaded its $4 billion acquisition by Bayer AG.

Elan Ezickson

Board Member

Elan Ezickson joined the board in 2019. He brings his extensive strategic, biopharmaceutical, operational, and capital formation expertise to Carmine Therapeutics.

Scientific Advisory Board

Prof. Harvey Lodish

Scientific Co-Founder & Board Member

Professor Lodish is a Founding Member of the Whitehead Institute for Biomedical Research. He is a Professor of Biology and a Professor of Biological Engineering at the Massachusetts Institute of Technology (MIT).

Dr. Jiahai Shi

Scientific Co-Founder & Advisor

Dr. Shi is presently an Associate Professor at the City University of Hong Kong. He aims to develop more novel therapies against unmet clinical needs.

Mark A. Kay M.D., Ph.D.

Scientific Advisor

Dr. Mark Kay is an acknowledged leader in the field of gene therapy and is a leading researcher in both viral and non-viral gene transfer vector systems.

Dr. Minh Le

Scientific Co-Founder & Advisor

Dr. Minh Le is presently an Assistant Professor and the Graduate Program Director at the Department of Pharmacology at the National University of Singapore.


Jianzhu Chen, Ph.D.

Scientific Advisor

Jianzhu Chen is a Professor of Biology at the Koch Institute for Integrative Cancer Research and at the Massachusetts Institute of Technology Department of Biology.